| # | Drug | Count |
|---|---|---|
| 0 | CARBOPLATIN | 12 |
| 1 | PACLITAXEL | 10 |
| 2 | NIVOLUMAB | 7 |
| 3 | CYCLOPHOSPHAMIDE | 3 |
| 4 | CYCLOPHOSPHAMIDE FOR INJECTION | 3 |
| 5 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 3 |
| 6 | FLUOROURACIL | 3 |
| 7 | FLUOROURACIL CREAM, 0.5% | 3 |
| 8 | IPILIMUMAB | 3 |
| 9 | CISPLATIN | 2 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | CEMIPLIMAB-RWLC | 1 | 0.0005 |
| 1 | METHYLCELLULOSE | 1 | 0.0004 |
| 2 | EPIRUBICIN HYDROCHLORIDE | 1 | 0.0002 |
| 3 | PACLITAXEL | 10 | 0.0001 |
| 4 | CARBOPLATIN | 12 | 0.0001 |
| 5 | NIVOLUMAB | 7 | 0.0001 |
| 6 | IPILIMUMAB | 3 | 0.0001 |
| 7 | PEMETREXED DISODIUM | 2 | 0.0001 |
| 8 | AXITINIB | 1 | 0.0001 |
| 9 | DURVALUMAB | 1 | 0.0000 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 7 | 0.0001 |
| 1 | CTLA-4-directed Blocking Antibody [EPC] | 3 | 0.0001 |
| 2 | Microtubule Inhibitor [EPC] | 10 | 0.0001 |
| 3 | Platinum-based Drug [EPC] | 14 | 0.0001 |
| 4 | Programmed Death Ligand-1 Blocker [EPC] | 1 | 0.0000 |
| 5 | Topoisomerase Inhibitor [EPC] | 2 | 0.0000 |
| 6 | Epidermal Growth Factor Receptor Antagonist [EPC] | 1 | 0.0000 |
| 7 | Alkylating Drug [EPC] | 3 | 0.0000 |
| 8 | Integrin Receptor Antagonist [EPC] | 1 | 0.0000 |
| 9 | Nucleoside Metabolic Inhibitor [EPC] | 3 | 0.0000 |